| Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors TA Yap, L Vidal, J Adam, P Stephens, J Spicer, H Shaw, J Ang, G Temple, ... Journal of clinical oncology 28 (25), 3965-3972, 2010 | 396 | 2010 |
| Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial NC Turner, B Kingston, LS Kilburn, S Kernaghan, AM Wardley, ... The Lancet Oncology 21 (10), 1296-1308, 2020 | 285 | 2020 |
| Targeting the S and G2 checkpoint to treat cancer T Chen, PA Stephens, FK Middleton, NJ Curtin Drug discovery today 17 (5-6), 194-202, 2012 | 224 | 2012 |
| First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor R Plummer, D Dua, N Cresti, Y Drew, P Stephens, M Foegh, S Knudsen, ... British journal of cancer 123 (4), 525-533, 2020 | 67 | 2020 |
| Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors R Plummer, P Stephens, L Aissat-Daudigny, A Cambois, G Moachon, ... Cancer chemotherapy and pharmacology 74, 257-265, 2014 | 42 | 2014 |
| Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer N Alsubhi, F Middleton, TMA Abdel-Fatah, P Stephens, R Doherty, ... Molecular Oncology 10 (2), 213-223, 2016 | 40 | 2016 |
| Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales C Chamberlain, SM Collin, P Stephens, J Donovan, A Bahl, ... British journal of cancer 111 (9), 1693-1702, 2014 | 39 | 2014 |
| mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition AJ Massey, P Stephens, R Rawlinson, L McGurk, R Plummer, NJ Curtin Molecular Oncology 10 (1), 101-112, 2016 | 24 | 2016 |
| Abstract GS3-06: results from the plasmaMATCH trial: a multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in … N Turner, B Kingston, L Kilburn, S Kernaghan, AM Wardley, I Macpherson, ... Cancer Research 80 (4_Supplement), GS3-06-GS3-06, 2020 | 20 | 2020 |
| Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009–2010 H1N1 pandemic: an ecological study PE Miller, A Rambachan, RJ Hubbard, J Li, AE Meyer, P Stephens, ... Public Library of Science 7 (9), e43491, 2012 | 14 | 2012 |
| Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP1-2 inhibitor) as single‑agent and in combination with … M Campone, R Plummer, P Stephens, Z Brakchi, L Aissat-Daudigny, ... Journal of Clinical Oncology 30 (15_suppl), 3052-3052, 2012 | 11 | 2012 |
| First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response … ER Plummer, D Dua, N Cresti, A Suder, Y Drew, P Stephens, M Foegh, ... Journal of Clinical Oncology 36 (15_suppl), 2505-2505, 2018 | 8 | 2018 |
| A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia R Coghlan, P Stephens, B Mwale, M Siyanga Malaria journal 17, 1-14, 2018 | 7 | 2018 |
| Olaratumab in combination with doxorubicin for the treatment of advanced soft tissue sarcoma: an evidence review group perspective of a national institute for health and care … IA Tikhonova, T Jones-Hughes, J Dunham, FC Warren, S Robinson, ... Pharmacoeconomics 36 (1), 39-49, 2018 | 7 | 2018 |
| Supply of neuraminidase inhibitors related to reduced influenza A (H 1 N 1) mortality during the 2009–2010 H 1 N 1 pandemic: summary of an ecological study PE Miller, A Rambachan, RJ Hubbard, J Li, AE Meyer, P Stephens, ... Influenza and Other Respiratory Viruses 7, 82-86, 2013 | 7 | 2013 |
| Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer A Bahl, W Wilson, J Ball, E Renninson, S Dubey, A Bravo, E Foulstone, ... The Breast 66, 69-76, 2022 | 5 | 2022 |
| Abstract P1-19-07: Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER … AM Wardley, L Kilburn, S Kernaghan, I Macpherson, RD Baird, ... Cancer Research 80 (4_Supplement), P1-19-07-P1-19-07, 2020 | 5* | 2020 |
| Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma R Plummer, D Dua, N Cresti, A Suder, Y Drew, V Prathapan, P Stephens, ... Annals of Oncology 25, iv151, 2014 | 5 | 2014 |
| Abstract P1-19-04: Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA … I Macpherson, L Kilburn, S Kernaghan, AM Wardley, RD Baird, ... Cancer Research 80 (4_Supplement), P1-19-04-P1-19-04, 2020 | 4 | 2020 |
| Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC). A Bahl, J Braybrooke, A Bravo, E Foulstone, J Ball, M Churn, S Dubey, ... Journal of Clinical Oncology 39 (15_suppl), 1008-1008, 2021 | 3 | 2021 |
